Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
3.
Eur J Clin Microbiol Infect Dis ; 38(7): 1333-1337, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30972588

ABSTRACT

The objective of this study is to evaluate the characteristics and outcome of elderly patients with Mediterranean spotted fever (MSF). This study was a prospective observational cohort study of all adult cases with confirmed MSF treated in a teaching hospital (1984-2015) to compare the characteristics of elderly patients (> 65 years) with younger adults. We identified 263 adult patients with MSF, and 53 (20.2%) were elderly. Severe MSF was more frequent in the elderly (26.4% vs. 10.5%; p = 0.002). Gastrointestinal symptoms, impaired consciousness, lung infiltrate, oedema, acute hearing loss, raised alanine transaminase, hyponatremia, and thrombocytopenia occurred more frequently in elderly patients, and arthromyalgia occurred less frequently. Most patients were treated with a single-day doxycycline regimen (two oral doses of 200 mg for 1 day). All patients recovered uneventfully. Fever disappeared 2.55 ± 1.16 days after treatment initiation in elderly patients, and the remaining symptoms disappeared after 3.65 ± 1.42 days. These figures were similar to non-elderly patients. Severe MSF was more frequent in elderly patients. Some clinical manifestations occurred with different frequencies in the elderly compared with younger patients. Single-day doxycycline therapy is an effective and well-tolerated treatment for MSF in elderly patients.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Boutonneuse Fever/complications , Boutonneuse Fever/drug therapy , Severity of Illness Index , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Boutonneuse Fever/diagnosis , Doxycycline/therapeutic use , Female , Humans , Male , Middle Aged , Prospective Studies , Thrombocytopenia , Tick-Borne Diseases/microbiology , Treatment Outcome , Young Adult
4.
Article in English | MEDLINE | ID: mdl-30249689

ABSTRACT

The aim of our study was to determine whether rifampin resistance emerges in human skin staphylococci after oral intake of rifaximin for surgical prophylaxis. Rifampin-resistant staphylococci appeared on the skin of 32 out of 74 patients (43.2%) two weeks after prophylactic treatment with rifaximin. In all cases, the resistant strains were coagulase-negative staphylococci. The resistance completely reverted after three months. This study shows the emergence of transient resistance to rifampin after rifaximin intake.


Subject(s)
Antibiotic Prophylaxis/methods , Rifampin/therapeutic use , Rifaximin/therapeutic use , Staphylococcal Infections/prevention & control , Staphylococcus/drug effects , Administration, Oral , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Colorectal Surgery , Drug Resistance, Multiple, Bacterial/drug effects , Elective Surgical Procedures , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Rifaximin/administration & dosage , Staphylococcal Infections/microbiology , Staphylococcus/isolation & purification
5.
Article in English | MEDLINE | ID: mdl-30150470

ABSTRACT

The objective of this study is to evaluate the results of single-day doxycycline therapy for Mediterranean spotted fever (MSF). This is a prospective cohort study of cases with confirmed MSF treated with the single-day doxycycline regimen in a teaching hospital from 1990 to 2015. Patients received two oral doses of 200 mg of doxycycline for 1 day. The outcomes evaluated were the time interval between the start of treatment and apyrexia, the time interval between the start of treatment and disappearance of other symptoms, and the adverse reactions to treatment and death. The study included 158 subjects, 18 of whom (11.4%) had a severe form of MSF and 31 (19.6%) were >65 years. The interval between onset of symptoms and start of treatment was 4.31 ± 1.54 days. All patients recovered uneventfully. Fever disappeared 2.55 ± 1.14 days after the start of treatment. The remaining symptoms (headache, arthromyalgia) disappeared 3.63 ± 1.35 days after the start of treatment. Only one patient had a delay in reaching apyrexia (8 days). The fever disappeared somewhat later in severe cases (median, 3 days; interquartile range [IQR], 2 to 4 days) than in nonsevere cases (median, 2 days; IQR, 2 to 3 days). Likewise, the remaining symptoms disappeared later in severe cases (median, 5 days; IQR, 4 to 6 days) than in nonsevere cases (median, 3 days; IQR, 3 to 4 days). The outcome was similar in both elderly and nonelderly patients. Eight patients had mild adverse effects possibly related to treatment. The results of the study confirm that single-day doxycycline therapy is an effective and well-tolerated treatment for MSF, including elderly patients and severe cases.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Boutonneuse Fever/drug therapy , Doxycycline/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Prospective Studies , Rickettsia conorii/drug effects , Young Adult
6.
Eur J Clin Microbiol Infect Dis ; 37(5): 969-975, 2018 May.
Article in English | MEDLINE | ID: mdl-29479635

ABSTRACT

The objective of this study is to evaluate the clinical and microbiological characteristics of bacteremia associated with pressure ulcers (BAPU) and factors associated with mortality. This study was a prospective observational cohort study of patients with BAPU at a teaching hospital between January 1984 and December 2015. Fifty-six episodes were included. The incidence of BAPU decreased from 2.78 cases per 10,000 hospital discharges in the period from 1984 to 1999 to 1.05 cases per 10,000 hospital discharges in the period from 2000 to 2015 (p < 0.001). In 20 cases (35.7%), the bacteremia was hospital-acquired, since it occurred more than 48 h after the hospital admission. The most frequent microorganisms isolated in blood culture were Staphylococcus aureus, Proteus spp., and Bacteroides spp. The bacteremia was polymicrobial in 14 cases (25.0%). Overall mortality was observed in 23 episodes (41.1%). The risk factors independently associated with mortality were hospital-acquired bacteremia (odds ratio [OR] 5.51, 95% confidence interval [95%CI] 1.24-24.40), polymicrobial bacteremia (OR 6.88, 95%CI 1.22-38.89), and serum albumin <23 g/L (OR 8.00, 95%CI 1.73-37.01). BAPU is an uncommon complication of pressure ulcers and is mainly caused by S. aureus, Proteus spp., and Bacteroides spp. In our hospital, the incidence of BAPU has declined in recent years, coinciding with the implementation of a multidisciplinary team aimed at preventing and treating chronic ulcers. Mortality rate is high, and hospital-acquired bacteremia, polymicrobial bacteremia, and serum albumin < 23 g/L are associated with increased mortality.


Subject(s)
Bacteremia/epidemiology , Bacteremia/etiology , Pressure Ulcer/complications , Aged , Aged, 80 and over , Bacteremia/mortality , Comorbidity , Cross Infection/epidemiology , Cross Infection/etiology , Cross Infection/mortality , Female , Hospital Mortality , Hospitals, Teaching , Humans , Male , Middle Aged , Prospective Studies , Risk Factors
7.
J Antimicrob Chemother ; 70(4): 1193-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25433010

ABSTRACT

OBJECTIVES: To analyse the possible relationship between consumption of old and new MRSA-active antibiotics and burden of MRSA in acute care hospitals in Catalonia during the period 2007-12. METHODS: Fifty-four hospitals participating in the VINCat Programme were included. Proportion of MRSA (resistant isolates of Staphylococcus aureus per 100 isolates of S. aureus tested), incidence of new cases of infection [new cases of MRSA per 1000 occupied bed-days (OBD)] and incidence of cases of bacteraemia (MRSA bacteraemia cases per 1000 OBD) were determined to estimate the annual MRSA burden. Antibiotic consumption was calculated in DDD/100 OBD. Cost was expressed in euros/100 OBD. RESULTS: MRSA rates remained stable over the study period, with the proportion of MRSA ranging from 20% to 22.82% in 2007 and 2012, respectively (P=0.864). Consumption of old MRSA-active antibiotics (vancomycin and teicoplanin) did not change significantly, with values from 1.51 to 2.07 DDD/100 OBD (P=0.693). Consumption of new MRSA-active antibiotics (linezolid and daptomycin) increased significantly, with values rising from 0.24 to 1.49 DDD/100 OBD (P<0.001). Cost increased by almost 200%. CONCLUSIONS: A widespread and steady increase in consumption of new MRSA-active antibiotics was observed among acute care hospitals in Catalonia, in spite of a stable MRSA burden. At the same time, consumption of old drugs remained stable. Such trends resulted in a significant increase in cost. Our findings suggest that factors other than the proportion of methicillin resistance among S. aureus may influence the use of old and new MRSA-active antibiotics in the clinical setting.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Utilization , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Staphylococcal Infections/epidemiology , Staphylococcal Infections/microbiology , Bacteremia/epidemiology , Bacteremia/microbiology , Hospitals , Humans , Incidence , Prevalence , Retrospective Studies , Spain/epidemiology
8.
Int J Infect Dis ; 26: 162-4, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25080353

ABSTRACT

OBJECTIVES: The aims of this study were to improve our understanding of the clinical forms of presentation of acute Q fever in Spain and to determine any possible relationships with geographical and seasonal factors. METHODS: This was a retrospective study of 183 cases of acute Q fever from three Spanish regions, Catalonia, Canary Islands, and La Rioja. RESULTS: The main clinical form of presentation was hepatitis (49.2%), followed by isolate febrile syndrome (31.7%) and pneumonia (19.1%). The proportion of cases presenting as pneumonia was significantly higher in La Rioja (40.7%) than in Catalonia (18.3%) or the Canary Islands (12.9%) (p=0.001). In Catalonia and the Canary Islands, most cases (52.1% and 57.6%, respectively) were diagnosed between March and June, whereas in La Rioja, most cases (51.8%) occurred between November and February. Overall, the proportion of cases presenting as pneumonia was significantly higher in the period from November to February (32.6%) than in the periods March-June (16.0%) and July-October (13.0%) (p=0.01). CONCLUSIONS: Our results suggest the existence of seasonal differences in the presentation of acute Q fever in Spain, with a higher proportion of pneumonic forms in the colder months. Furthermore, we confirmed the existence of geographical differences, with a higher proportion of pneumonic forms in the region of La Rioja, in the north of the country.


Subject(s)
Q Fever/diagnosis , Seasons , Adult , Female , Hepatitis/complications , Hepatitis/diagnosis , Humans , Male , Middle Aged , Q Fever/complications , Q Fever/epidemiology , Retrospective Studies , Spain
9.
Enferm Infecc Microbiol Clin ; 30 Suppl 3: 20-5, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22776150

ABSTRACT

The VINCat Program is a standardized surveillance program of healthcare infections in Catalonia, Spain. This program includes monitoring of surgical site infections (SSI) of elective colorectal surgery. The aim of this study was to define SSI rates in colorectal surgery among VINCat hospitals over a period of 4 years. We included consecutive elective colorectal interventions performed in VINCat hospitals from 2007 to 2010. Follow-up visits were performed 30 days after surgery. Prospective monitoring of SSI in colorectal surgery was performed according to standardized VINCat methodology. SSI was defined according to the Centers for Disease Control (CDC) and surgical risk factors according to the National Healthcare Safety Network (NHSN) classification. From 2007 to 2010, 49 centers performed 10,104 surgical procedures. The cumulative incidence of SSI was 20.8% (95% CI: 20.03-21.63). The annual cumulative SSI incidence rate did not vary significantly over the study period; however, there were significant differences among hospital infection rates. The relative frequency of organ-space infection increased from 25% in 2007 to 40% in 2010 (p<0.001). Laparoscopic surgery also increased (28% in 2007 to 42% in 2010, p<0.001). However, no changes were observed in mean surgery duration, ASA score and degree of surgical contamination. The VINCat Program incorporated a large number of Catalan hospitals that participated in standardized monitoring of colorectal surgery. The cumulative incidence rate of SSI for colorectal surgery was 20.8%, although there were large variations between hospitals.


Subject(s)
Colon/surgery , Cross Infection/epidemiology , Digestive System Surgical Procedures/statistics & numerical data , Elective Surgical Procedures/statistics & numerical data , Population Surveillance , Rectum/surgery , Surgical Wound Infection/epidemiology , Aged , Aged, 80 and over , Female , Hospital Bed Capacity/statistics & numerical data , Hospitals, Public/classification , Hospitals, Public/statistics & numerical data , Humans , Incidence , Male , Middle Aged , Population Surveillance/methods , Prospective Studies , Risk Factors , Spain/epidemiology
10.
Enferm Infecc Microbiol Clin ; 30 Suppl 3: 39-42, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22776153

ABSTRACT

Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of healthcare-related infection. Surveillance and prevention of MRSA is a priority in infection control programs. The aim of this study was to describe rates and trends of MRSA colonization or infection in 40 hospitals participating in the VINCat Program from 2008 to 2010. The study included all patients treated in acute care areas of participating hospitals. Hospitals were stratified into 3 groups based on size. The following annual indicators were reported: Methicillin-resistance rate, incidence density of new cases of MRSA and incidence density of MRSA bacteremia. Between 2008 and 2010, the yearly mean rate of resistance to methicillin remained stable for the study period (24%-25%), while the mean incidence of new cases of MRSA decreased from 0.65 to 0.54 cases per 1000 patient-days (p=NS) and the mean incidence of MRSA bacteremia decreased from 0.06 to 0.05 cases per 1,000 patient-days (p=NS). The implementation of a MRSA surveillance system in hospitals that participated in the VINCat Program provides information on the situation of each institution and facilitated interhospital comparisons in order to establish appropriate preventive measures.


Subject(s)
Cross Infection/epidemiology , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Population Surveillance , Staphylococcal Infections/epidemiology , Bacteremia/epidemiology , Bacteremia/microbiology , Bacteremia/prevention & control , Cross Infection/prevention & control , Hospital Bed Capacity/statistics & numerical data , Hospitals, Public/classification , Hospitals, Public/statistics & numerical data , Humans , Incidence , Length of Stay/statistics & numerical data , Methicillin Resistance , Prospective Studies , Risk Factors , Spain/epidemiology , Staphylococcal Infections/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...